MUC1 and adenocarcinoma: In fact, multiple bladder tumor cell types, including transitional cell carcinomas, adenocarcinomas, and squamous cell carcinoma, exhibited upregulation in membrane complement inhibitors (CD46: 77%, CD55: 55%, CD59: 59%) after the cell samples were incubated with anti-MUC1 (mucin-1) antibodies.30